|
1. Beevers, D.G., The atlas of heart disease and stroke. Journal of Human Hypertension, 2005. 19(6): p. 505-505.
2. Roth, G.A., et al., Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019. 2020. 76(25): p. 2982-3021.
3. Day, I.S.C.f.W.T., Thrombosis: a major contributor to the global disease burden. J Thromb Haemost, 2014. 12(10): p. 1580-1590.
4. Francula-Zaninovic, S. and I.A. Nola, Management of Measurable Variable Cardiovascular Disease' Risk Factors. Curr Cardiol Rev, 2018. 14(3): p. 153-163.
5. Masana, L., et al., Is there a role for lifestyle changes in cardiovascular prevention? What, when and how? Atheroscler Suppl, 2017. 26: p. 2-15.
6. Casas, R., et al., Nutrition and Cardiovascular Health. Int J Mol Sci, 2018. 19(12):3988.
7. Yusuf, S., et al., Global Burden of Cardiovascular Diseases. 2001. 104(22): p. 2746-2753.
8. Stamler, J., et al., Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. Jama, 1999. 282(21): p. 2012-2018.
9. Sabatine, M.S., et al., Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med, 2017. 376(18): p. 1713-1722.
10. Baigent, C., et al., Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 2010. 376(9753): p. 1670-1681.
11. Arnett, D.K., et al., 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019. 140(11): p. e563-e595.
12. Abifadel, M., et al., Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet, 2003. 34(2): p. 154-156.
13. Rashid, S., et al., Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A, 2005. 102(15): p. 5374-5379.
14. Reiner, Z., Resistance and intolerance to statins. Nutr Metab Cardiovasc Dis, 2014. 24(10): p. 1057-1066.
15. Packard, C., et al., Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges. Heart, 2021. 107(17): p. 1369-1375.
16. Yadav, K., M. Sharma, and K.C. Ferdinand, Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons. Nutr Metab Cardiovasc Dis, 2016. 26(10): p. 853-862.
17. Lambert, G., et al., The PCSK9 decade. J Lipid Res, 2012. 53(12): p. 2515-2524.
18. Page, M.M. and G.F. Watts, PCSK9 inhibitors - mechanisms of action. Aust Prescr, 2016. 39(5): p. 164-167.
19. Alexander, R.W., Hypertension and the Pathogenesis of Atherosclerosis. 1995. 25(2): p. 155-161.
20. Gidding, S.S. and N.B. Allen, Cholesterol and Atherosclerotic Cardiovascular Disease: A Lifelong Problem. 2019. 8(11): p. e012924.
21. Henning, R.J., Obesity and obesity-induced inflammatory disease contribute to atherosclerosis: a review of the pathophysiology and treatment of obesity. Am J Cardiovasc Dis, 2021. 11(4): p. 504-529.
22. Stary, H.C., et al., A Definition of Advanced Types of Atherosclerotic Lesions and a Histological Classification of Atherosclerosis. 1995. 92(5): p. 1355-1374.
23. Sanz, J. and Z.A. Fayad, Imaging of atherosclerotic cardiovascular disease. Nature, 2008. 451(7181): p. 953-957.
24. Moriya, J., Critical roles of inflammation in atherosclerosis. J Cardiol, 2019. 73(1): p. 22-27.
25. Libby, P., Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol, 2012. 32(9): p. 2045-2051.
26. Mayerl, C., et al., Atherosclerosis research from past to present--on the track of two pathologists with opposing views, Carl von Rokitansky and Rudolf Virchow. Virchows Arch, 2006. 449(1): p. 96-103.
27. Risk Factors in Coronary Heart Disease. 1964. 61(5_Part_1): p. 888-899.
28. Libby, P., et al., Atherosclerosis. Nat Rev Dis Primers, 2019. 5(1): p. 56.
29. Ravnskov, U., Is atherosclerosis caused by high cholesterol? QJM: An International Journal of Medicine, 2002. 95(6): p. 397-403.
30. Carmena, R., P. Duriez, and J.C. Fruchart, Atherogenic lipoprotein particles in atherosclerosis. Circulation, 2004. 109(23 Suppl 1): p. III2-7.
31. Boren, J., et al., Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J, 2020. 41(24): p. 2313-2330.
32. Havel, R.J., H.A. Eder, and J.H. Bragdon, The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest, 1955. 34(9): p. 1345-1353.
33. Gofman, J.W., F.T. Lindgren, and H. Elliott, Ultracentrifugal studies of lipoproteins of human serum. J Biol Chem, 1949. 179(2): p. 973-979.
34. Miller, Y.I., et al., Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ Res, 2011. 108(2): p. 235-248.
35. Navab, M., et al., The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res, 2004. 45(6): p. 993-1007.
36. Kuzuya, M., et al., Role of lipoprotein-copper complex in copper catalyzed-peroxidation of low-density lipoprotein. Biochim Biophys Acta, 1992. 1123(3): p. 334-341.
37. Itabe, H., T. Obama, and R. Kato, The Dynamics of Oxidized LDL during Atherogenesis. J Lipids, 2011. 2011: p. 418313.
38. Sawamura, T., et al., An endothelial receptor for oxidized low-density lipoprotein. Nature, 1997. 386(6620): p. 73-77.
39. Salvayre, R., et al., Oxidized low-density lipoprotein-induced apoptosis. Biochim Biophys Acta, 2002. 1585(2-3): p. 213-221.
40. Chen, C.H., et al., Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription. Circulation, 2003. 107(16): p. 2102-2108.
41. Yang, C.Y., et al., Isolation, characterization, and functional assessment of oxidatively modified subfractions of circulating low-density lipoproteins. Arterioscler Thromb Vasc Biol, 2003. 23(6): p. 1083-1090.
42. Avogaro, P., G.B. Bon, and G. Cazzolato, Presence of a modified low density lipoprotein in humans. 1988. 8(1): p. 79-87.
43. Demuth, K., et al., A Cytotoxic Electronegative LDL Subfraction Is Present in Human Plasma. 1996. 16(6): p. 773-783.
44. Estruch, M., et al., Electronegative LDL: a circulating modified LDL with a role in inflammation. Mediators Inflamm, 2013. 2013: p. 181324.
45. Tang, D., et al., Electronegative LDL circulating in smokers impairs endothelial progenitor cell differentiation by inhibiting Akt phosphorylation via LOX-1. J Lipid Res, 2008. 49(1): p. 33-47.
46. Chang, P.Y., et al., Aspirin protects human coronary artery endothelial cells against atherogenic electronegative LDL via an epigenetic mechanism: a novel cytoprotective role of aspirin in acute myocardial infarction. Cardiovasc Res, 2013. 99(1): p. 137-145.
47. Wang, G.-J., et al., Negatively charged L5 as a naturally occurring atherogenic low-density lipoprotein. BioMedicine, 2012. 2(4): p. 147-154.
48. Chan, H.C., et al., Highly electronegative LDL from patients with ST-elevation myocardial infarction triggers platelet activation and aggregation. Blood, 2013. 122(22): p. 3632-3641.
49. Chang, C.T., et al., Electronegative Low-density Lipoprotein Increases Coronary Artery Disease Risk in Uremia Patients on Maintenance Hemodialysis. Medicine (Baltimore), 2016. 95(2): p. e2265.
50. Hsu, J.F., et al., Low-density lipoprotein electronegativity is a novel cardiometabolic risk factor. PLoS One, 2014. 9(9): p. e107340.
51. Chu, C.S., et al., Range of L5 LDL levels in healthy adults and L5's predictive power in patients with hyperlipidemia or coronary artery disease. Sci Rep, 2018. 8(1): p. 11866.
52. Chu, C.S., et al., Clinical Significance of Electronegative Low-Density Lipoprotein Cholesterol in Atherothrombosis. Biomedicines, 2020. 8(8):254.
53. Lu, J., et al., Electronegative LDL impairs vascular endothelial cell integrity in diabetes by disrupting fibroblast growth factor 2 (FGF2) autoregulation. Diabetes, 2008. 57(1): p. 158-166.
54. Wang, Y.C., et al., Human electronegative LDL induces mitochondrial dysfunction and premature senescence of vascular cells in vivo. Aging Cell, 2018. 17(4): p. e12792.
55. Chen, W.Y., et al., Role of apolipoprotein E in electronegative low-density lipoprotein-induced mitochondrial dysfunction in cardiomyocytes. Metabolism, 2020. 107: p. 154227.
56. Antico Arciuch, V.G., et al., Mitochondrial regulation of cell cycle and proliferation. Antioxid Redox Signal, 2012. 16(10): p. 1150-1180.
57. Anderson, A.J., et al., Mitochondria—hubs for regulating cellular biochemistry: emerging concepts and networks. 2019. 9(8): p. 190126.
58. Osellame, L.D., T.S. Blacker, and M.R. Duchen, Cellular and molecular mechanisms of mitochondrial function. Best Pract Res Clin Endocrinol Metab, 2012. 26(6): p. 711-723.
59. Sagan, L., On the origin of mitosing cells. J Theor Biol, 1967. 14(3): p. 255-274.
60. Kuhlbrandt, W., Structure and function of mitochondrial membrane protein complexes. BMC Biol, 2015. 13: p. 89.
61. Cogliati, S., J.A. Enriquez, and L. Scorrano, Mitochondrial Cristae: Where Beauty Meets Functionality. Trends Biochem Sci, 2016. 41(3): p. 261-273.
62. Anderson, S., et al., Sequence and organization of the human mitochondrial genome. Nature, 1981. 290(5806): p. 457-465.
63. Needs, H.I., et al., Interplay between Mitochondrial Protein Import and Respiratory Complexes Assembly in Neuronal Health and Degeneration. Life (Basel), 2021. 11 ;11(5):432.
64. Bause, A.S. and M.C. Haigis, SIRT3 regulation of mitochondrial oxidative stress. Exp Gerontol, 2013. 48(7): p. 634-639.
65. He, J., et al., Inhibition of Mitochondrial Oxidative Damage Improves Reendothelialization Capacity of Endothelial Progenitor Cells via SIRT3 (Sirtuin 3)-Enhanced SOD2 (Superoxide Dismutase 2) Deacetylation in Hypertension. Arterioscler Thromb Vasc Biol, 2019. 39(8): p. 1682-1698.
66. Chen, M.L., et al., Trimethylamine-N-Oxide Induces Vascular Inflammation by Activating the NLRP3 Inflammasome Through the SIRT3-SOD2-mtROS Signaling Pathway. J Am Heart Assoc, 2017. 6(9) :e006347.
67. Dikalova, A.E., et al., Mitochondrial Deacetylase Sirt3 Reduces Vascular Dysfunction and Hypertension While Sirt3 Depletion in Essential Hypertension Is Linked to Vascular Inflammation and Oxidative Stress. Circ Res, 2020. 126(4): p. 439-452.
68. Dikalova, A.E., et al., Sirt3 Impairment and SOD2 Hyperacetylation in Vascular Oxidative Stress and Hypertension. Circ Res, 2017. 121(5): p. 564-574.
69. Mastrodonato, M., et al., Altered distribution of caveolin-1 in early liver steatosis. Eur J Clin Invest, 2011. 41(6): p. 642-651.
70. Fridolfsson, H.N., et al., Regulation of intracellular signaling and function by caveolin. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2014. 28(9): p. 3823-3831.
71. Fridolfsson, H.N., et al., Mitochondria-localized caveolin in adaptation to cellular stress and injury. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2012. 26(11): p. 4637-4649.
72. Schilling, J.M., B.P. Head, and H.H. Patel, Caveolins as Regulators of Stress Adaptation. Mol Pharmacol, 2018. 93(4): p. 277-285.
73. Sun, S.W., et al., Caveolae and caveolin-1 mediate endocytosis and transcytosis of oxidized low density lipoprotein in endothelial cells. Acta Pharmacol Sin, 2010. 31(10): p. 1336-1342.
74. Matarazzo, S., et al., Cholesterol-lowering drugs inhibit lectin-like oxidized low-density lipoprotein-1 receptor function by membrane raft disruption. Mol Pharmacol, 2012. 82(2): p. 246-254.
75. Ramirez, C.M., et al., Caveolin-1 Regulates Atherogenesis by Attenuating Low-Density Lipoprotein Transcytosis and Vascular Inflammation Independently of Endothelial Nitric Oxide Synthase Activation. Circulation, 2019. 140(3): p. 225-239.
76. Youle, R.J. and M. Karbowski, Mitochondrial fission in apoptosis. Nature Reviews Molecular Cell Biology, 2005. 6(8): p. 657-663.
77. Lu, J., et al., Mediation of Electronegative Low-Density Lipoprotein Signaling by LOX-1. 2009. 104(5): p. 619-627.
78. Bhatti, J.S., G.K. Bhatti, and P.H. Reddy, Mitochondrial dysfunction and oxidative stress in metabolic disorders - A step towards mitochondria based therapeutic strategies. Biochim Biophys Acta Mol Basis Dis, 2017. 1863(5): p. 1066-1077.
79. Scott, I. and R.J. Youle, Mitochondrial fission and fusion. Essays Biochem, 2010. 47: p. 85-98.
80. Raskob, G.E., et al., Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol, 2014. 34(11): p. 2363-2371.
81. Shapiro, M.D., H. Tavori, and S. Fazio, PCSK9: From Basic Science Discoveries to Clinical Trials. Circ Res, 2018. 122(10): p. 1420-1438.
82. Ding, Z., et al., Cross-talk between LOX-1 and PCSK9 in vascular tissues. Cardiovasc Res, 2015. 107(4): p. 556-567.
83. Zhang, X., et al., Cav-1 (Caveolin-1) Deficiency Increases Autophagy in the Endothelium and Attenuates Vascular Inflammation and Atherosclerosis. Arterioscler Thromb Vasc Biol, 2020. 40(6): p. 1510-1522.
|